12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial

12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial

Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines...

Full description

Bibliographic Details
Main Authors: Bingfeng Han, Wu Liu, Juan Du, Hanyu Liu, Tianshuo Zhao, Shubo Yang, Shuai Wang, Sihui Zhang, Bei Liu, Yaqiong Liu, Fuqiang Cui
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Vaccines
Subjects:
diabetes mellitus
hepatitis B vaccines
vaccination
persistent immunogenicity
revaccination
Online Access:https://www.mdpi.com/2076-393X/9/12/1407

Similar Items

Similar Items